Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2002

01-02-2002

Lack of in Vitro – in Vivo Correlation of a Novel Investigational Anticancer Agent, SH 30

Authors: Srinivasu Poondru, Ralph E. Parchment, Vivek Purohit, Patricia LoRusso, Jerome P. Horwitz, Stuart T. Hazeldine, Lisa Polin, Thomas Corbett, Bhaskara R. Jasti

Published in: Investigational New Drugs | Issue 1/2002

Login to get access
Metadata
Title
Lack of in Vitro – in Vivo Correlation of a Novel Investigational Anticancer Agent, SH 30
Authors
Srinivasu Poondru
Ralph E. Parchment
Vivek Purohit
Patricia LoRusso
Jerome P. Horwitz
Stuart T. Hazeldine
Lisa Polin
Thomas Corbett
Bhaskara R. Jasti
Publication date
01-02-2002
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 1/2002
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1014457510073

Other articles of this Issue 1/2002

Investigational New Drugs 1/2002 Go to the issue

OriginalPaper

Anticancer Activity and Protein Phosphatase 1 and 2A Inhibition of a New Generation of Cantharidin Analogues

OriginalPaper

A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

OriginalPaper

Phase I/II Study of Gemcitabine plus Vinorelbine in Non-Small Cell Lung Cancer

OriginalPaper

Chemotherapy-Induced Palmar-Plantar Erythrodysesthesia Syndrome – Recall Following Different Chemotherapy Agents

OriginalPaper

Partial Circumvention of P-Glycoprotein-Mediated Multidrug Resistance by Doxorubicin-14-O-Hemiadipate

OriginalPaper

Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Renal Cell Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits